Position in XENE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$53,717,019
-$27,287,501 QoQ
Shares Held
889,944
-36.1% QoQ
Ownership
0.919%
of shares outstanding
% of Portfolio
2.59%
of 13F equity value
Holder Rank
#28
of 314 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in XENE Over Time
Shares Held
Position Value (USD)
Derivatives in XENE
reported options exposure · as of Dec 31, 2025CallValue
$0
CallShares
0
PutValue
$24,637,554
PutShares
549,700
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Caligan Partners LP holds $1,404,383,722 across 23 Biotechnology names. XENE ranks #7 (3.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
1,961,795 | $367,404,967 | |
| 2 | ABVX |
Abivax S.A.
|
1,557,924 | $207,608,952 | |
| 3 | PCVX |
Vaxcyte, Inc.
|
2,188,636 | $127,225,410 | |
| 4 | EXEL |
Exelixis, Inc.
|
1,553,262 | $84,512,985 | |
| 5 | TNGX |
Tango Therapeutics, Inc.
|
2,500,103 | $78,153,219 | |
| 6 | AVTX |
Avalo Therapeutics, Inc.
|
3,163,866 | $58,468,243 | |
| 7 | XENE |
Xenon Pharmaceuticals Inc.
This page
|
889,944 | $53,717,019 | |
| 8 | ADMA |
Adma Biologics, Inc.
|
5,725,007 | $47,918,308 |
All Filings in XENE
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $53,717,019 | 889,944 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $81,004,520 | 1,393,027 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $24,635,985 | 549,665 | Shares | Sole | 2026-02-17 | |
| 2025-12-31 | $24,637,554 | 549,700 | Put | Sole | 2026-02-17 | |
| 2025-09-30 | $17,849,284 | 444,565 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||